Characteristics | NO. of cases(%) | Sum(n = 300) | |||
---|---|---|---|---|---|
training cohort(n = 180) | validation cohort(n = 120) | training cohort(n = 150) | validation cohort(n = 150) | ||
Age(16y ~ 84y) | |||||
< 60 | 110(61.1) | 72(60) | 81(54) | 101(67.3) | 182(60.7) |
≥ 60 | 70(38.9) | 48(40) | 69(46) | 49(32.7) | 18(39.3) |
Gender | |||||
Male | 127(70.6) | 88(73.3) | 110(73.3) | 105(70) | 215(71.7) |
Female | 53(29.4) | 32(26.7) | 40(26.7) | 45(30) | 85(28.3) |
WHO/ISUP Grading | |||||
I-II | 137(76.1) | 91(75.8) | 108(72) | 120(80) | 228(76) |
III-IV | 43(23.9) | 29(24.2) | 42(28) | 30(20) | 72(24) |
TNM stage | |||||
I-II | 161(89.4) | 105(87.5) | 136(90.7) | 130(86.7) | 266(88.7) |
III-IV | 19(10.6) | 15(12.5) | 14(9.3) | 20(13.3) | 34(11.3) |
SSIGN | |||||
1–4 | 167(92.8) | 114(95) | 139(92.7) | 142(94.7) | 281(93.7) |
≥ 5 | 13(7.2) | 6(5) | 11(7.3) | 8(5.3) | 19(6.3) |